Biotech Industry Flexes New Muscle; Investors Pump Cash Into Research
Investors are pouring money into biotechnology industry in last year, changing dynamics of industry that has long relied on deep pockets of pharmaceutical companies to bring its technology and drugs to market; biotech companies do not need drug companies' money as badly as they once did--but drug companies still want to license biotech drugs; as balance of power shifts from pharmaceutical giants to biotech companies, like OSI Pharmaceuticals, smaller companies are able to arrange licensing deals that leave them with larger shares of profits, and in some cases, direct roles in selling drugs they develop; in first half of 2000, biotechnology companies raised $22.1 billion from public and private financings, well above $12 billion raised in all of 1999 and nearly triple $8.1 billion raised in 1998; big drug companies are courting OSI Pharmaceuticals now that Pfizer Inc gave back its full rights to one of their drug combinations as part of antitrust agreement to acquire Warner-Lambert; OSI chief executive Colin Goddard comments; graph; photos (M)
